Natera, Inc.
NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30234% above fair value
$378.92−35.38 (-8.54%)
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera BGI Genomics License Agreement by Quarter
BGI Genomics License Agreement — Current Contract Liability ($M) [legacy through Q3 2025] ($M)
Natera BGI Genomics License Agreement: $0.50M in Q3 2025, unchanged from a year earlier.
Latest, Q3 2025
0.50
Period ended Sep 30, 2025
Change on a year earlier
0.0%
0.50 in Q3 2024
History
21 quarters
Since Q2 2019
Sources
21
Documents cited below
Where the Q3 2025 figure comes from
Source: Form 10-Q (2025-11-07) ↗
Reported in Form 10-K/10-Q Note — Collaborative & Licensing Arrangements (2019–2025Q3).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | BGI Genomics License Agreement — Current Contract Liability ($M) [legacy through Q3 2025] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2025 | Sep 30, 2025 | 0.50 | 0.0% | Form 10-Q (2025-11-07) ↗ |
| Q2 2025 | Jun 30, 2025 | 0.50 | 0.0% | Form 10-Q (2025-08-08) ↗ |
| Q1 2025 | Mar 31, 2025 | 0.50 | -58.3% | Form 10-Q (2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 0.50 | -58.3% | Form 10-K (2025-02-28) ↗ |
| Q3 2024 | Sep 30, 2024 | 0.50 | – | Form 10-Q (2024-11-12) ↗ |
| Q2 2024 | Jun 30, 2024 | 0.50 | – | Form 10-Q (2024-08-09) ↗ |
| Q1 2024 | Mar 31, 2024 | 1.20 | – | Form 10-Q (2024-05-10) ↗ |
| Q4 2023 | Dec 31, 2023 | 1.20 | +1,100.0% | Form 10-K (2024-02-29) ↗ |
| Q4 2022 | Dec 31, 2022 | 0.10 | -96.9% | Form 10-K (2023-03-01) ↗ |
| Q3 2022 | Sep 30, 2022 | 0.70 | -80.0% | Form 10-Q (2022-11-09) ↗ |
| Q2 2022 | Jun 30, 2022 | 6.40 | +100.0% | Form 10-Q (2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 7.50 | +134.4% | Form 10-Q (2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 3.20 | -17.9% | Form 10-K (2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 3.50 | -25.5% | Form 10-Q (2021-11-05) ↗ |
| Q2 2021 | Jun 30, 2021 | 3.20 | +540.0% | Form 10-Q (2021-08-06) ↗ |
| Q1 2021 | Mar 31, 2021 | 3.20 | – | Form 10-Q (2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 3.90 | – | Form 10-K (2021-02-26) ↗ |
| Q3 2020 | Sep 30, 2020 | 4.70 | -61.0% | Form 10-Q (2020-11-06) ↗ |
| Q2 2020 | Jun 30, 2020 | 0.50 | -96.7% | Form 10-Q (2020-08-07) ↗ |
| Q3 2019 | Sep 30, 2019 | 12.1 | – | Form 10-Q (2019-11-08) ↗ |
| Q2 2019 | Jun 30, 2019 | 15 | – | Form 10-Q (2019-08-09) ↗ |
Cite this data
StockData. (2026). Natera BGI Genomics License Agreement ($M), quarterly Q2 2019–Q3 2025 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-bgi-current
See every metric in the Natera KPI table. Data updated Nov 2, 2026.